H.C. Wainwright Upgrades Adlai Nortye's Price Target Amid Positive Outlook on Lead Asset
On April 20, H.C. Wainwright upgraded its price target for Adlai Nortye (NASDAQ:ANL) to $20 from $16 while maintaining a Buy rating due to the potential best-in-class potency of AN9025, the company's lead asset. Additionally, on April 16, Adlai Nortye announced a private investment in public equity financing expected to raise approximately $150 million.
Tickers: $EXAS
Topics: Analyst Rating Biopharmaceutical Cancer Therapies Private Placement RAS Inhibitor